
Kevin E. Weddington
Examiner (ID: 369, Phone: (571)272-0587 , Office: P/1629 )
| Most Active Art Unit | 1629 |
| Art Unit(s) | 1629, 2899, 1614, 1205 |
| Total Applications | 3441 |
| Issued Applications | 2215 |
| Pending Applications | 423 |
| Abandoned Applications | 827 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17790378
[patent_doc_number] => 20220249469
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => IMPROVED TREATMENT USING EYP001
[patent_app_type] => utility
[patent_app_number] => 17/627704
[patent_app_country] => US
[patent_app_date] => 2020-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6566
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17627704
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/627704 | Treatment using EYP001 | Jul 16, 2020 | Issued |
Array
(
[id] => 17874292
[patent_doc_number] => 11446283
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-20
[patent_title] => Methods and dosing regimens using ibudilast and a second agent for cancer therapy
[patent_app_type] => utility
[patent_app_number] => 16/926441
[patent_app_country] => US
[patent_app_date] => 2020-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 15124
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 160
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16926441
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/926441 | Methods and dosing regimens using ibudilast and a second agent for cancer therapy | Jul 9, 2020 | Issued |
Array
(
[id] => 20127881
[patent_doc_number] => 12370181
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-29
[patent_title] => Regimens of estrogen receptor antagonists
[patent_app_type] => utility
[patent_app_number] => 17/625184
[patent_app_country] => US
[patent_app_date] => 2020-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 27
[patent_no_of_words] => 6350
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17625184
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/625184 | Regimens of estrogen receptor antagonists | Jul 5, 2020 | Issued |
Array
(
[id] => 20127881
[patent_doc_number] => 12370181
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-29
[patent_title] => Regimens of estrogen receptor antagonists
[patent_app_type] => utility
[patent_app_number] => 17/625184
[patent_app_country] => US
[patent_app_date] => 2020-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 27
[patent_no_of_words] => 6350
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17625184
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/625184 | Regimens of estrogen receptor antagonists | Jul 5, 2020 | Issued |
Array
(
[id] => 17554962
[patent_doc_number] => 11311619
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-26
[patent_title] => Integrin activator vaccine compositions
[patent_app_type] => utility
[patent_app_number] => 16/920506
[patent_app_country] => US
[patent_app_date] => 2020-07-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 7
[patent_no_of_words] => 14999
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16920506
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/920506 | Integrin activator vaccine compositions | Jul 2, 2020 | Issued |
Array
(
[id] => 18869761
[patent_doc_number] => 11857541
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-02
[patent_title] => Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis
[patent_app_type] => utility
[patent_app_number] => 16/916145
[patent_app_country] => US
[patent_app_date] => 2020-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 6561
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16916145
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/916145 | Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis | Jun 29, 2020 | Issued |
Array
(
[id] => 16539259
[patent_doc_number] => 20200405672
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-31
[patent_title] => METHODS FOR TREATING PSYCHIATRIC DISEASES AND DISORDERS AND THE SYMPTOMS THEREOF IN A SUBJECT BY ADMINISTERING AN ANTAGONIST OF THE NA+-K+-2CL- CATION-CHLORIDE COTRANSPORTER ISOFORM 1 (NKCC1)
[patent_app_type] => utility
[patent_app_number] => 16/915746
[patent_app_country] => US
[patent_app_date] => 2020-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8680
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16915746
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/915746 | Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1) | Jun 28, 2020 | Issued |
Array
(
[id] => 18215190
[patent_doc_number] => 11590102
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-02-28
[patent_title] => Anti-methanogenic lovastatin analogs or derivatives and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/915427
[patent_app_country] => US
[patent_app_date] => 2020-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 31861
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 113
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16915427
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/915427 | Anti-methanogenic lovastatin analogs or derivatives and uses thereof | Jun 28, 2020 | Issued |
Array
(
[id] => 18084329
[patent_doc_number] => 11534436
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-12-27
[patent_title] => Methods for treating depressive symptoms
[patent_app_type] => utility
[patent_app_number] => 16/913404
[patent_app_country] => US
[patent_app_date] => 2020-06-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 15995
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 186
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16913404
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/913404 | Methods for treating depressive symptoms | Jun 25, 2020 | Issued |
Array
(
[id] => 16539334
[patent_doc_number] => 20200405747
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-31
[patent_title] => OPHTHALMIC COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 16/911833
[patent_app_country] => US
[patent_app_date] => 2020-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8571
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16911833
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/911833 | Ophthalmic compositions | Jun 24, 2020 | Issued |
Array
(
[id] => 16837772
[patent_doc_number] => 20210145784
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => GLYCOGEN OR POLYSACCHARIDE STORAGE DISEASE TREATMENT METHOD
[patent_app_type] => utility
[patent_app_number] => 16/911195
[patent_app_country] => US
[patent_app_date] => 2020-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18729
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16911195
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/911195 | GLYCOGEN OR POLYSACCHARIDE STORAGE DISEASE TREATMENT METHOD | Jun 23, 2020 | Abandoned |
Array
(
[id] => 17602858
[patent_doc_number] => 11331327
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-17
[patent_title] => Antibacterial use of halogenated salicylanilides
[patent_app_type] => utility
[patent_app_number] => 16/899821
[patent_app_country] => US
[patent_app_date] => 2020-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 13665
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16899821
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/899821 | Antibacterial use of halogenated salicylanilides | Jun 11, 2020 | Issued |
Array
(
[id] => 16341621
[patent_doc_number] => 20200306271
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => ANTIBACTERIAL USE OF HALOGENATED SALICYLANILIDES
[patent_app_type] => utility
[patent_app_number] => 16/899830
[patent_app_country] => US
[patent_app_date] => 2020-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13582
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16899830
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/899830 | Antibacterial use of halogenated salicylanilides | Jun 11, 2020 | Issued |
Array
(
[id] => 16341619
[patent_doc_number] => 20200306269
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => ANTIBACTERIAL USE OF HALOGENATED SALICYLANILIDES
[patent_app_type] => utility
[patent_app_number] => 16/899812
[patent_app_country] => US
[patent_app_date] => 2020-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13572
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16899812
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/899812 | Antibacterial use of halogenated salicylanilides | Jun 11, 2020 | Issued |
Array
(
[id] => 16686703
[patent_doc_number] => 20210069178
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => Method for Inducing a Sustained Immune Response
[patent_app_type] => utility
[patent_app_number] => 16/898557
[patent_app_country] => US
[patent_app_date] => 2020-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27371
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16898557
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/898557 | Method for inducing a sustained immune response | Jun 10, 2020 | Issued |
Array
(
[id] => 16450935
[patent_doc_number] => 20200360361
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-19
[patent_title] => Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer
[patent_app_type] => utility
[patent_app_number] => 16/885570
[patent_app_country] => US
[patent_app_date] => 2020-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20089
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16885570
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/885570 | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer | May 27, 2020 | Issued |
Array
(
[id] => 16389480
[patent_doc_number] => 20200330421
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-22
[patent_title] => COMPOSITION CONTAINING MONOACETYLDIACYLGLYCEROL COMPOUND AS ACTIVE INGREDIENT FOR INHIBITING BLOOD CANCER OR METASTASIS
[patent_app_type] => utility
[patent_app_number] => 16/886280
[patent_app_country] => US
[patent_app_date] => 2020-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5552
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16886280
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/886280 | COMPOSITION CONTAINING MONOACETYLDIACYLGLYCEROL COMPOUND AS ACTIVE INGREDIENT FOR INHIBITING BLOOD CANCER OR METASTASIS | May 27, 2020 | Abandoned |
Array
(
[id] => 16435601
[patent_doc_number] => 20200352926
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer
[patent_app_type] => utility
[patent_app_number] => 16/885767
[patent_app_country] => US
[patent_app_date] => 2020-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20125
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16885767
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/885767 | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer | May 27, 2020 | Issued |
Array
(
[id] => 16435601
[patent_doc_number] => 20200352926
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer
[patent_app_type] => utility
[patent_app_number] => 16/885767
[patent_app_country] => US
[patent_app_date] => 2020-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20125
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16885767
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/885767 | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer | May 27, 2020 | Issued |
Array
(
[id] => 17525706
[patent_doc_number] => 11298372
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-12
[patent_title] => Composition for ameliorating loss of hair and graying of hair, and use thereof
[patent_app_type] => utility
[patent_app_number] => 16/885930
[patent_app_country] => US
[patent_app_date] => 2020-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 45
[patent_figures_cnt] => 66
[patent_no_of_words] => 13933
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16885930
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/885930 | Composition for ameliorating loss of hair and graying of hair, and use thereof | May 27, 2020 | Issued |